Development of implantable hydroxypropyl-β-cyclodextrin coated polycaprolactone nanoparticles for the controlled delivery of docetaxel to solid tumors

Journal of Inclusion Phenomena and Macrocyclic Chemistry

Volumn 80, Issue 1-2, 2014, Pages 9-15

  Varan, Cem ^a   Bilensoy, Erem ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Cyclodextrins; Docetaxel; Nanoparticle; Polycaprolactone; Polyethylene glycol; Tumor

Indexed keywords

EID: 84939879823     PISSN: 09230750     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10847-014-0422-6     Document Type: Article

References (39)

1. Pathak, P., Kathiyar, V.K.: Multi-functional nanoparticles and their role in cancer drug delivery - a review. Azonano. 3, 1-17 (2007)
2. Luo, Y., Prestwich, G.D.: Cancer-targeted polymeric drugs. Curr. Cancer Drug Targets 2(3), 209-226 (2002)
3. Bharali, D.J., Khalil, M., Gurbuz, M.: Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int. J. Nanomed. 4, 1-7 (2009)
4. Kim, K.Y.: Nanotechnology platforms and physiological challenges for cancer therapeutics. Nanomed. Nanotechnol. Biol. Med. 3(2), 103-110 (2007)
5. Guenard, D., Voegelein-Gueritte, F., Potier, P.: Taxol and Taxotere: discovery, chemistry, and structure-activity relationships. Acc. Chem. Res. 26, 160-167 (1993)
6. Verweij, J., Clavel, M., Chevalier, B.: Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): not simply two of a kind. Ann. Oncol. 5, 495-505 (1994)
7. Sampath, P., Rhines, L.D., DiMeco, F., Tyler, B.M., Park, M.C., Brem, H.: Interstitial docetaxel (Taxotere): novel treatment for experimental malignant glioma. J. Neurooncol. 80(1), 9-17 (2006)
8. Moes, J., Koolen, S., Huitema, A., Schellens, J., Beijnen, J., Nuijen, B.: Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel. Eur. J. Pharm. Biopharm. 83(1), 87-94 (2013)
9. Immordino, M.L., Brusa, P., Arpicco, S., Stella, B., Dosio, F., Cattel, L.: Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J. Controll. Release 91(3), 417-429 (2003)
10. Baker, J., Ajani, J., Scotte, F., Winther, D., Martin, M., Aapro, M.S., Minckwitz, G.: Docetaxel-related side effects and their management. Eur. J. Oncol. Nurs. 13, 49-59 (2009)
11. Mora-Huertas, C., Fessi, H., Elaissari, A.: Polymer-based nanocapsules for drug delivery. Int. J. Pharm. 385, 113-142 (2010)
12. Zelphati, O., Uyechi, L., Barron, L., Szoka, F.: Biochimica et Biophysica Acta (BBA)-Lipids and Lipid. Metabolism 1390, 119-133 (1998)
13. Quintanar-Guerrero, D., Allémann, E., Fessi, H., Doelker, E.: Drug development and industrial pharmacy. Drug Dev. Ind. Pharm. 24, 1113-1128 (1998)
14. Parveen, S., Misra, R., Sahoo, S.: Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomed. Nanotechnol. Biol. Med. 8(2), 147-166 (2012)
15. Lundqvist, M., Stigler, J., Elia, G., Lynch, I.: Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. PNAS 15, 14265-14270 (2008)
16. Bilensoy, E.: Cationic nanoparticles for cancer therapy. Expert Opin. Drug Deliv. 7, 795-809 (2010)
17. Woodruff, M.A., Hutmacher, D.W.: The return of a forgotten polymer-polycaprolactone in the 21st century. Prog. Polym. Sci. 35, 1217-1256 (2010)
18. Sinha, V.R., Bansal, K., Kaushik, R., Kumria, R., Trehan, A.: Poly-epsilon-caprolactone microspheres and nanospheres: an overview. Int. J. Pharm. 278(1), 1-23 (2004)
19. Gad, S.C.: Pharmaceutical Manufacturing Handbook: Production and Processes, 544-545. Wiley-Interscience, New Jersey (2008), ISBN 978-0-470-25958-0
20. Schubert, S., Delaney, J.T., Schubert, U.S.: Nanoprecipitation and nanoformulation of polymers: from history to powerful possibilities beyond poly(lactic acid). R. Soc. Chem. Soft Matter 7, 1581-1588 (2011)
21. Gref, R., Lück, M., Quellec, P., Marchand, M., Dellacherie, E., Harnisch, S.: 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B 18, 301-313 (2000)
22. Choi, C., Chae, S.Y., Kim, T.-H., Jang, M.-K., Cho, C.S., Nah, J.W.: Preparation and characterizations of poly(ethylene glycol)-poly(ε-caprolactone) block copolymer nanoparticles. Bull. Korean Chem. Soc. 26(4), 523-528 (2005)
23. Zhou, S., Deng, X., Yang, H.: Biodegradable poly(ε-caprolactone)-poly(ethylene glycol) block copolymers: characterization and their use as drug carriers for a controlled delivery system. Biomaterials 24, 3563-3570 (2003)
24. Liu, Q., Li, R., Zhu, Z., Qian, X., Guan, W., Yu, L.: Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles. Int. J. Pharm. 430(1-2), 350-358 (2012)
25. Wei, X.W., Gong, C.Y., Gou, M.Y., Fu, S.Z., Guo, Q.F., Shi, S.: Biodegradable poly(epsilon-caprolactone)-poly(ethylene glycol) copolymers as drug delivery system. Int. J. Pharm. 381(1), 1-18 (2009)
26. Li, R., Li, X., Xie, L., Ding, D., Hu, Y., Qian, X.: Preparation and evaluation of PEG-PCL nanoparticles for local tetradrine delivery. Int. J. Pharm. 379, 158-166 (2009)
27. Challa, R., Ahuja, A., Ali, J., Khar, R.K.: Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech 6(2), E329-E357 (2005)
28. Fessi, H., Devissaguet, J.P., Thies, C.: Process for the preparation of dispersible colloidal systems of a substance in the form of nanospheres. US Patent 5,118,528 (1998)
29. Brigger, I., Dubernet, C., Couvreur, P.: Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54, 631-651 (2002)
30. Win, K.Y., Feng, S.S.: Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26(15), 2713-2722 (2005)
31. Muller, R.H., Jacobs, C., Kayser, O.: Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47(1), 3-19 (2001)
32. Hans, M.L., Lowman, A.M.: Biodegradable nanoparticles for drug delivery and targeting. Curr. Opin. Solid State Mater. Sci. 6(4), 319-327 (2002)
33. Boudad, H., Legrand, P., Lebas, G., Cheron, M., Duchêne, D., Ponchel, G.: Combined hydroxypropyl-β-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. Int. J. Pharm. 218(1-2), 113-124 (2001)
34. Cameselle, C., Reddy, K.R., Darko-Kagya, K., Khodadoust, A.: Effect of dispersant on transport of nanoscale iron particles in soils: zeta potential measurements and column experiments. J. Environ. Eng. 139(1), 23-33 (2013)
35. Xin, H., Chen, L., Gu, J., Ren, X., Wei, Z., Luo, J., Chen, Y., Jiang, X., Sha, X., Fang, X.: Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(e-caprolactone) nanoparticles: in vitro and in vivo evaluation. Int. J. Pharm. 402, 238-247 (2010)
36. Bilensoy, E., Hincal, A.A.: Recent advances and future directions in amphiphilic cyclodextrin nanoparticles. Expert Opin. Drug Deliv. 6(11), 1161-1173 (2009)
37. Thiele, C., Auerbach, D., Jung, G., Wenz, G.: Inclusion of chemotherapeutic agents in substituted b-cyclodextrin derivatives. J. Incl. Phenom. Macrocycl. Chem. 69, 303-307 (2011)
38. Park, M.H., Keum, C.G., Song, J.Y., Kim, D., Cho, C.W.: A novel aqueous parenteral formulation of docetaxel using prodrugs. Int. J. Pharm. 462, 1-7 (2014)
39. Agüeros, M., Zabaleta, V., Espuelas, S., Campanero, M.A., Irache, J.M.: Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles. J. Controll. Release 145, 2-8 (2010)